Company Profile
Denali Therapeutics Stock Price, News & Analysis
- Ticker:
- DNLI
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
24.73 USD (+1.27%)
Close
Last updated: August 6, 2026
3.07B USD
Market cap
Why the stock is moving
The latest monitored company update is “Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights.” The corresponding closing-price reaction is not yet available.
Company overview
Blood-Brain-Barrier Delivery
Denali Therapeutics develops medicines for neurodegenerative and lysosomal-storage diseases. Its TransportVehicle platform uses transferrin-receptor binding to carry enzymes, proteins and oligonucleotides across the blood-brain barrier.
AVLAYAH
AVLAYAH, or tividenofusp alfa, is an enzyme TransportVehicle therapy approved for neurologic manifestations of Hunter syndrome in selected pediatric patients. It is the first commercial validation of Denali's delivery platform.
DNL593
DNL593 is a progranulin replacement therapy delivered with the protein TransportVehicle for GRN-related frontotemporal dementia.
DNL628
DNL628 is an oligonucleotide TransportVehicle candidate designed to reduce tau production in Alzheimer's disease through systemically delivered genetic medicine.
DNL126
DNL126 is an enzyme TransportVehicle replacement therapy for Sanfilippo syndrome type A, intended to address neurologic and systemic manifestations of the lysosomal-storage disease.
Future catalysts
Phase 1/2 data for DNL593 in GRN-related frontotemporal dementia by the end of 2026.
Recent news
- 01
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Source: Denali Therapeutics
- 02
- 03
- 04
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Source: Denali Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Denali Therapeutics (DNLI)?
Denali Therapeutics (DNLI) most recently closed at 24.73 USD, a +1.27% move versus the previous session.
What is the market cap of Denali Therapeutics (DNLI)?
Denali Therapeutics currently has a market capitalization of 3.07B USD on BioPharmSignal.
What does Denali Therapeutics do?
Blood-Brain-Barrier Delivery Denali Therapeutics develops medicines for neurodegenerative and lysosomal-storage diseases. Its TransportVehicle platform uses transferrin-receptor binding to carry enzymes, proteins and oligonucleotides across the blood-brain barrier. AVLAYAH AVLAYAH, or tividenofusp alfa, is an enzyme TransportVehicle therapy approved for...
On which exchange is DNLI stock listed?
Denali Therapeutics (DNLI) is associated with NASDAQ, United States, MedTech.
What is Blood-Brain-Barrier?
Blood-Brain-Barrier Delivery Denali Therapeutics develops medicines for neurodegenerative and lysosomal-storage diseases.
Which conditions is Denali Therapeutics targeting with Blood-Brain-Barrier?
Denali Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Denali Therapeutics describe recent progress with Blood-Brain-Barrier?
Phase 1/2 data for DNL593 in GRN-related frontotemporal dementia by the end of 2026.
What is Delivery?
Blood-Brain-Barrier Delivery Denali Therapeutics develops medicines for neurodegenerative and lysosomal-storage diseases.